Fine Foods & Pharmaceuticals N.T.M. SpA · MIL:FF

Fine Foods & Pharmaceuticals N.T.M. SpA — Q1 2024 Earnings Presentation

39 slides from Fine Foods & Pharmaceuticals N.T.M. SpA's earnings presentation, May 15, 2024

  1. Slide 1: Q1 2024 Results Presentation

    Q1 2024 RESULTS PRESENTATION 15/05/24

  2. Slide 2: Index

    FINE FOODS Q1 2024 INDEX 2 RESULTS PRESENTATION Index WE CREATE FINANCIALS SHAREHOLDING VALUE STRUCTURE INVESTOR BACK UP INFORMATION ESG DETAILS & CONTACTS

  3. Slide 3: We Create Value

    FINE FOODS Q1 2024 3 RESULTS PRESENTATION WE CREATE VALUE

  4. Slide 4: Fine Foods at a glance

    FINE FOODS Q1 2024 WE CREATE VALUE 4 RESULTS PRESENTATION Fine Foods Italian independent CDMO active in Strong partnership with at a glance the pharmaceutical, nutraceutical multinational clients in all our and cosmetics industries through reference markets three Business Units Stable presence of Ei

  5. Slide 5: Strong corporate culture

    FINE FOODS Q1 2024 WE CREATE VALUE 5 RESULTS PRESENTATION Strong corporate culture Three different integrated and cross-functional FINE FOODS business units committed to Fine Foods’ key CORPORATE business principles STRUCTURE PHARMA

  6. Slide 6: European reference markets

    FINE FOODS Q1 2024 WE CREATE VALUE 6 RESULTS PRESENTATION European CAGR PHARMA1 (€BN) 5.2% PHARMA2 – CDMO reference 9.2% 18% 23% Italy markets 632.6 775.1 5% Market Germany France 445.3 6% value: United Kingdom 13.5 €BN Spain 20% 12% Greece Others 16% 2019a 2023e 2027e FOOD – DIETARY SUPPLEMENT3 (€B

  7. Slide 7: Consistently outperforming reference markets

    FINE FOODS Q1 2024 WE CREATE VALUE 7 RESULTS PRESENTATION Consistently Reference markets show high steady growth and resilience during recessions Fine Foods has substantially outgrown its reference end-markets in the last decade, with outperforming 2023 sales at 2.9X the 2013 level reference Europea

  8. Slide 8: Selection of products

    FINE FOODS Q1 2024 WE CREATE VALUE 8 RESULTS PRESENTATION Selection of products • Nutraceuticals (Nutra BU) • Pharmaceuticals (Pharma BU) • Cosmetics (Cosmetic BU)

  9. Slide 9: What we do

    FINE FOODS Q1 2024 WE CREATE VALUE 9 RESULTS PRESENTATION NUTRA PHARMA COSMETIC What we do PHARMACEUTICAL FORMS Capsules Tablets Powders Granules Liquids Creams Gels Toothpaste Parfum Cross-fertilised innovation & Lotions is implemented by exploiting our expertise in different fields, best practices

  10. Slide 10: Flexible and integrated business model

    FINE FOODS Q1 2024 WE CREATE VALUE 10 RESULTS PRESENTATION Flexible NUTRACEUTICALS AND COSMETICS and integrated Concept Development Regulatory Compliance Formulation Production Distribution business model Fine Foods is positioned within the value creation chain of pharmaceuticals, PHARMACEUTICALS nu

  11. Slide 11: Customers' loyalty

    FINE FOODS Q1 2024 WE CREATE VALUE 11 RESULTS PRESENTATION 2020 Customers’ 2010 loyalty 2000 Retained key clients acquired before 2000 with several new ones added afterwards, including those derived from our recent acquisitions in the cosmetic industry. Note: Sigma-Tau & Alfa Wassermann (now Alfasig

  12. Slide 12: Strong holistic ESG

    FINE FOODS Q1 2024 WE CREATE VALUE 12 RESULTS PRESENTATION 2010 2013 2015 2019 2022 Strong Organisation, management and • Sustainability report • Impact report (Benefit Corporation) holistic control systems • Diversity and Inclusion program under Legislative Standard which Standard describing Decree

  13. Slide 13: R&D for efficient and high-quality product development

    FINE FOODS Q1 2024 WE CREATE VALUE 13 RESULTS PRESENTATION R&D for OPPORTUNITY LAB efficient and Formulae databank ➝ Wide range of ready-to-use high-quality product formulations product development INNOVATION LAB Innovative products ➝ A lab to offer out-of-the-box ideas 136 employees NUTRACEUTICALS

  14. Slide 14: Three production plants located in a European cluster of excellence

    FINE FOODS Q1 2024 WE CREATE VALUE 14 RESULTS PRESENTATION BREMBATE Three production LOMBARDIA plants located in a European 1 BERGAMO cluster of 2 ZINGONIA Excellence MILANO 3 TRENZANO Italy and Lombardia, where our plants are located, are a cluster of excellence for our sectors. This has a positive

  15. Slide 15: Financials

    FINE FOODS Q1 2024 15 RESULTS PRESENTATION FINANCIALS

  16. Slide 16: Q1 2024 consolidated revenue

    FINE FOODS Q1 2024 FINANCIALS 16 RESULTS PRESENTATION Q1 2024 (€M) consolidated 65.6 65.6 revenue Q1 2024 Revenue stable vs the extraordinary results of Q1 2023 Q1 2023 Q1 2024 REVENUE BREAK-DOWN Nutra Pharma Cosmetic 40.7 39.8 16.8 17.6 8.1 8.1 Q1 2023 Q1 2024 Q1 2023 Q1 2024 Q1 2023 Q1 2024

  17. Slide 17: Q1 2024 consolidated revenue

    FINE FOODS Q1 2024 FINANCIALS 17 RESULTS PRESENTATION Q1 2024 (€M) consolidated 65.6 66.1 65.6 revenue 61.9 58.2 Q1 2024 followed the +21.7% 54 52.2 extraordinary growth in FY 2023 and 50.8 49.8 the all-time Q4 2023 record results Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 20

  18. Slide 18: Q1 2024 EBITDA

    FINE FOODS Q1 2024 FINANCIALS 18 RESULTS PRESENTATION Q1 2024 Q1 2024 vs Q1 2023 REVENUE % EBITDA (€M) +11.5% 7.9 8.9 Q1 2024 EBITDA reflected a decreased impact of raw material costs on revenue compared to Q1 2023 and an improvement in the organization efficiency Q1 2023 Q1 2024 Q1 2024 vs Q4 2023

  19. Slide 19: Q1 2024 EBIT

    FINE FOODS Q1 2024 FINANCIALS 19 RESULTS PRESENTATION Q1 2024 Q1 2024 vs Q1 2023 (€M) REVENUE % EBIT 4.2 5.1 Q1 2024 EBIT benefited from the above cost item dynamics Q1 2023 Q1 2024 Q1 2024 vs Q4 2023 REVENUE % (€M) -1.1 5.1 Q4 2023 Q1 2024

  20. Slide 20: Q1 2024 Net Result

    FINE FOODS Q1 2024 FINANCIALS 20 RESULTS PRESENTATION Q1 2024 Q1 2024 vs Q1 2023 REVENUE % Net Result (€M) The Net Result for Q1 2024 was nearly unchanged compared to Q1 2023 2.9 2.8 Q1 2023* Q1 2024 Q1 2024 vs Q4 2023 REVENUE % (€M) -1.8 2.8 Q4 2023 Q1 2024 * In Q1 2023, the Parent Company's asset

  21. Slide 21: Robust capital structure

    FINE FOODS Q1 2024 FINANCIALS 21 RESULTS PRESENTATION Robust capital NET FINANCIAL POSITION (€M) structure NFP 31/12/2023 Net Income Amortisation ∆ NWC Others CAPEX Buy Back NFP 31/03/2024 Net Financial Position (NFP) was stable, (43.6) (43.6) highlighting a positive cash flow resulting 3.8 (2.6) 1.

  22. Slide 22: Guidelines for future growth

    FINE FOODS Q1 2024 FINANCIALS 22 RESULTS PRESENTATION Guidelines for Despite the current international economic and geopolitical situation, and temporary shifts in some customers' inventory management, the target markets continue to future growth expand. Fine Foods is set on growing its market share

  23. Slide 23: Shareholding Structure

    FINE FOODS Q1 2024 23 RESULTS PRESENTATION SHAREHOLDING STRUCTURE

  24. Slide 24: Shareholding structure

    FINE FOODS Q1 2024 SHAREHOLDING 24 RESULTS PRESENTATION STRUCTURE Shareholding FINE FOODS SHARES N. OF SHARES (Million) % FLOATING (ON LISTED SHARES) structure ~53.9% LISTED SHARES 22.1 86% UNLISTED SHARES* 3.5 14% As of 15.05.2024 TOTAL EQUITY CAPITAL 25.6 100% 4.2% * Unlisted shares are Multiple V

  25. Slide 25: Investor Information & Contacts

    FINE FOODS Q1 2024 25 RESULTS PRESENTATION INVESTOR INFORMATION & CONTACTS

  26. Slide 26: Investor Information

    FINE FOODS Q1 2024 INVESTOR INFORMATION 26 RESULTS PRESENTATION AND CONTACTS Investor MARKET EURONEXT STAR MILAN Information ISIN CODE IT0005215329 TICKER FF BANCA AKROS S.p.A. Analyst: Gian Marco Gadini E-mail: gianmarco.gadini@bancaakros.it SPECIALIST Recommendation: Buy Target Price: € 12.50 Last

  27. Slide 27: Why Fine Foods?

    FINE FOODS Q1 2024 INVESTOR INFORMATION 27 RESULTS PRESENTATION AND CONTACTS Why Fine Foods? Reliability Performance Positioning • Holistic sustainability • Solid track record with • Unique presence in since foundation a 10-year revenue Nutra, Pharma and CAGR of 11% Cosmetic sectors • Advanced HR ma

  28. Slide 28: Contacts

    FINE FOODS Q1 2024 INVESTOR INFORMATION 28 RESULTS PRESENTATION AND CONTACTS Contacts Fine Foods & Pharmaceuticals N.T.M. S.p.A. Tel. +39 035 4821382 Investor Relations & Communication Advisor: Michaela M. Carboni Investor Relations: ir@finefoods.it Media Relations: media.relations@finefoods.it

  29. Slide 29: Disclaimer

    FINE FOODS Q1 2024 INVESTOR INFORMATION 29 RESULTS PRESENTATION AND CONTACTS Disclaimer This document has been prepared by Fine Foods & The information contained in this document, unless Pharmaceuticals N.T.M. S.p.A. for the sole purpose otherwise specified is only current as of the date of this des

  30. Slide 30: Back Up ESG Details

    FINE FOODS Q1 2024 30 RESULTS PRESENTATION BACK UP ESG DETAILS

  31. Slide 31: Fine Foods' Group sustainability pillars

    FINE FOODS Q1 2024 BACK UP – ESG DETAILS 31 RESULTS PRESENTATION People Fine Foods’ Group Environment Ethics & sustainability Governance pillars Supply Sustainable Chain Products Land Development

  32. Slide 32: ESG main initiatives and results

    FINE FOODS Q1 2024 BACK UP – ESG DETAILS 32 RESULTS PRESENTATION Social ESG Environment Governance main CIRCULAR ECONOMY • Programs for reduction of WE ATTRACT ~ 11,000 applications/year BOARD OF DIRECTORS • 3 Women out of 7 Directors initiatives environmental impact of waste • 3 Independent Directo

  33. Slide 33: Ratings, ESG Commitment and Certifications

    FINE FOODS Q1 2024 BACK UP – ESG DETAILS 33 RESULTS PRESENTATION Ratings, RATINGS ESG Sedex Member Commitment and ESG COMMITMENT Certifications BENEFIT CORPORATION 231 Organizational, Since 2021 managerial and control New membership to the models to prevent network of companies on crimes Diversity a

  34. Slide 34: People

    FINE FOODS Q1 2024 BACK UP – ESG DETAILS 34 RESULTS PRESENTATION People WE ATTRACT ~ 11.000 WOMEN ~ 47% of managers SAFETY AT WORK Management system for applications/year ~ 43% of Board health and safety We are committed members is internationally to creating an certified since 2014** environment ta

  35. Slide 35: Corporate Governance

    FINE FOODS Q1 2024 BACK UP – ESG DETAILS 35 RESULTS PRESENTATION Corporate →3 Women out of 7 Directors Governance →3 Independent Directors out of 7 →2 Non-executive Directors out of 7 Our governance is structured around an ESG responsible approach. It allows us to pursue a sustainable growth while a

  36. Slide 36: Sustainable products

    FINE FOODS Q1 2024 BACK UP – ESG DETAILS 36 RESULTS PRESENTATION OUR SERVICES Sustainable products Environmental Product carbon Product labelling footprint calculation eco-design Support and service to consultation support support develop products that provide environmental, social and economic bene

  37. Slide 37: Relations with local communities

    FINE FOODS Q1 2024 BACK UP – ESG DETAILS 37 RESULTS PRESENTATION Relations SOCIAL RESPONSIBILITY TRADE ASSOCIATIONS with local communities ~500 students involved in meetings on sustainability and orientation issues 9 students accepted for internships and school-to-work projects MAIN COLLABORATIONS 5

  38. Slide 38: Suppliers' ESG management

    FINE FOODS Q1 2024 BACK UP – ESG DETAILS 38 RESULTS PRESENTATION Suppliers’ ESG ENVIRONMENTAL AND SOCIAL ASSESSMENT OF OUR SUPPLIERS management 89% Value of purchases of raw materials and packaging from suppliers assessed by EcoVadis on ESG criteria 92% Value of purchases of raw materials and packag

  39. Slide 39: Environment

    FINE FOODS Q1 2024 BACK UP – ESG DETAILS 39 RESULTS PRESENTATION Environment We are committed to sustainably use our resources and reduce our environmental impact. CLIMATE WATER RESOURCES CIRCULAR ECONOMY ENVIRONMENT PROTECTION • -19% CO2 • Programs for • Programs for emissions intensity reduction o

Fine Foods & Pharmaceuticals N.t.m. — Q1 2024 Earnings Presentation on 6ix